INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare services fertility company, today announced that on May 27, 2026, it received a delinquency notice (the "Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Notice relates to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "10-K"), and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the "10-Q").

The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq, and the Company's common stock will continue to trade on Nasdaq under the symbol "IVF" at this time.

The Company filed the 10-K with the SEC on June 2, 2026, and is working diligently to complete and file the 10-Q as soon as possible. The previous delay in filing the 10-K was due to additional time required to review certain complex accounting matters, including its tax provision, variable interest entities, and derivative accounting.

The Company expects the pending first quarter 10-Q to reflect further progress on its core business objectives, which included the completion of a $7.5 million financing in January 2026 and the acquisition of Family Beginnings, an Indiana-based fertility clinic, which together strengthened the Company's operations, balance sheet and overall growth strategy.